

1. An enzyme that produces plasma protein fragments having an inhibitory activity to metastasis and growth of cancer.

2. The enzyme that produces plasma protein fragments of claim 1 which has the following properties: (a) it has a molecular weight of about 45 kDa as measured by SDS electrophoresis under non-reduced condition; (b) it has the N-terminal amino acid sequence LVR IPLHKFT; (c) it degrades plasma proteins at an acidic pH range of not more than pH 5.0 to produce plasma protein fragments having an inhibitory activity to metastasis and growth of cancer; and (d) it is an aspartic enzyme having a high homology to a cathepsin D precursor.

15 3. The enzyme that produces plasma protein fragments of claim 1 or 2 wherein said plasma proteins to be fragmented are selected from the group consisting of plasminogen, fibronectin, vitronectin and human hepatocyte growth factor (HGF).

20 4. The enzyme that produces plasma protein fragments of any of claims 1 to 3 wherein said enzyme cleaves plasminogen at 73L-74F and/or 451L-452P to produce fragments comprising Kringles 1 to 4 of plasminogen.

5. Plasma protein fragments that are produced from
25 degradation by the action of the enzyme that produces

Sub B3
plasma protein fragments as set forth in any of claims 1 to 4 and have an inhibitory activity to metastasis and growth of cancer.

6. The plasma protein fragments of claim 5 that are
5 derived from plasma proteins selected from the group consisting of plasminogen, fibronectin, vitronectin and human hepatocyte growth factor (HGF).

7. The plasma protein fragments of claim 5 or 6 comprising Kringles 1 to 4 of plasminogen.

10 8. The plasma protein fragments of claim 5 or 6 comprising heparin-binding domain of fibronectin.

9. A process for preparing plasma protein fragments having an inhibitory activity to metastasis and growth of cancer, which comprises reacting plasma components with the enzyme that produces plasma protein fragments as set forth in any of claims 1 to 4.
15

10. The process of claim 9 wherein said process further comprises specifically isolating the plasma protein fragments having an inhibitory activity to metastasis and
20 growth of cancer with a resin having a heparin carrier.

11. A medicament for treating and preventing disease conditions associated with vascularization such as cancer (solid cancer), diabetic retinosis and rheumatism comprising as a major ingredient the enzyme that produces
25 plasma protein fragments as set forth in any of claims 1 to

09806568-073001
Sub B3

4.

12. A medicament for treating and preventing cancer comprising as a major ingredient the enzyme that produces plasma protein fragments as set forth in any of claims 1 to

5 4.

13. A medicament for treating and preventing disease conditions associated with vascularization such as cancer (solid cancer), diabetic retinosis and rheumatism comprising as a major ingredient the plasma protein fragments as set forth in any of claims 5 to 8.

14. A medicament for treating and preventing cancer comprising as a major ingredient the plasma protein fragments as set forth in any of claims 5 to 8.

15

09806568.073001
Sub
B7